![\"\"](\"https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2021\/06\/\u05e8\u05e2\u05e0\u05df-300.jpg\")
<\/h1>\nPhD Student. Under the supervision of Dr. Guy Cohen and Dr. Arie Lev Gruzman<\/p>\n Development of a novel IL-33 screening platform for dermatological-relevant disorders<\/strong><\/p>\n Interleukin\u201033 (IL-33) is a tissue-derived nuclear cytokine from the IL-1 family, whose members are associated with pro and anti-inflammatory responses through the MyD88 pathway. IL-1 members are also involved with innate immune responses, which occur during acute inflammation and chronic inflammatory conditions.IL-33 is mostly expressed in endothelial cells, epithelial cells and fibroblasts. Once it is released from the cells, it starts to activate immune cells that express its receptor, ST2 (IL- 1RL1), such as mast cells, group 2 innate lymphoid cells (ILC2s) and regulatory T cells (Tregs). This process leads to an immune response. However, in some cases, such as atopic dermatitis, an over release of IL-33 may lead to a damaging over inflammatory response. To prevent this condition, IL-33 activity can be reduced by endogenous regulations, such as secretion of sST2 and deactivation of the binding activity of IL-33 by cysteine moieties oxidation. However, to date, no specific and effective drug exists to reduce the deleterious effects of IL-33. The objective of this study is to develop a new improved screening system to evaluate new APIs that will be developed by computer modeling and will be synthesized accordingly.<\/p>\n Nrf2 Activation by SK-119 Attenuates Oxidative Stress, UVB, and LPS-Induced Damage.<\/a><\/p>\n![\"\"](\"https:\/\/adssc.org\/en\/wp-content\/uploads\/2018\/07\/email.png\")
raanan@adssc.org<\/a>
\n![\"\"](\"https:\/\/adssc.org\/en\/wp-content\/uploads\/2018\/01\/researchgate.png\")
Researchgate<\/a><\/p>\nAbstract:<\/h4>\n
Publications:<\/h4>\n